NCT02493582View on ClinicalTrials.gov

The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

July 31, 2030

Study Completion Date

July 31, 2033

Conditions
Adenocarcinoma of Lung
Interventions
BIOLOGICAL

Cytokine-Induced Killer Cells

CIKs are used with Apatinib to treat lung adenocarcinoma patients with wild-type EGFR

DRUG

Apatinib

Advanced lung adenocarcinoma patients with wild-type EGFR take Apatinib 850mg qd by mouth.

All Listed Sponsors
lead

The First People's Hospital of Changzhou

OTHER